Targets › TFRC
2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 3; Metabolic and endocrine, Hematology; next expected readout Dec 2026.
Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. (UniProt, P02786)
Open in Phaseline: the race on TFRC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| JCR Pharmaceuticals | Pabinafusp Alfa (JR-141) Transferrin receptor binding agent | TFRC, TFR2 | Phase 3 | Mucopolysaccharidosis II | Dec 2026 |
| Halia Therapeutics | HT-6184 CD71 transferrin receptor antagonist | TFRC | Phase 2 | Myelodysplastic Syndrome | – |
Mucopolysaccharidosis II (3) Myelodysplastic Syndrome (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.